Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder | Zendy

Cellina Ching | Zendy; Guy D. Eslick | Zendy; Alison Poulton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder

Author(s) -

Cellina Ching,

Guy D. Eslick,

Alison Poulton

Publication year - 2019

Publication title -

jama pediatrics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.004

H-Index - 183

eISSN - 2168-6211

pISSN - 2168-6203

DOI - 10.1001/jamapediatrics.2019.0905

Subject(s) - methylphenidate , medicine , jadad scale , attention deficit hyperactivity disorder , adverse effect , clinical trial , randomized controlled trial , medline , psychiatry , pediatrics , pharmacology , cochrane library , political science , law

Evidence on the titration of stimulant medications for attention-deficit/hyperactivity disorder (ADHD) is lacking. However, this lack of evidence has not prevented medication guidelines from specifying apparently arbitrary dose limitations, which could discourage clinicians from titrating methylphenidate to higher and, perhaps for some patients, more efficacious doses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research